{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-003160","form_type":"8-K","ticker":"PLX","cik":"0001006281","company_name":"Protalix BioTherapeutics, Inc.","filed_at":"2024-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.069128+00:00","generated_at":"2026-06-04T18:37:42.370346+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Protalix reports 2023 net income $8.3M vs loss; Elfabrio approvals, $20M milestone","bullets":["Revenue from goods $40.4M (+60% YoY); license/R&D services $25.1M (+13%).","Net income $8.3M ($0.12 diluted EPS) vs net loss $14.9M in 2022.","Cash $44.6M at year-end; Elfabrio approved in US, EU, UK, Switzerland, Israel.","$20M milestone from Chiesi triggered by FDA approval; $17.5M Elfabrio sales post-approval.","PRX-115 Phase I fully enrolled; results expected Q2 2024. New chairman appointed."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-003160","json":"https://secwatch.observer/filing/0001558370-24-003160.json","markdown":"https://secwatch.observer/filing/0001558370-24-003160.md","text":"https://secwatch.observer/filing/0001558370-24-003160.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006281/000155837024003160/0001558370-24-003160-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006281/000155837024003160/plx-20240314x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T18:37:42.370346+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5537355b6e651b30616139de1b09ba91e905af51","claim":"Protalix BioTherapeutics, Inc. reported financial results for the fiscal year ended December 31, 2023.","evidence_excerpt":"On March 14, 2024, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal year ended December 31, 2023 and provided a business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1006281/000155837024003160/0001558370-24-003160-index.htm","confidence":0.75,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}